Document resource
Cave and Harnden are right that passive pharmacovigilance is no longer adequate for modern medicines regulation.1 The burden of adverse drug reactions makes this a patient safety problem, not merely a data management inconvenience.2 The unresolved question is how the proposed UK Health Data Research Service will convert faster access to data into earlier regulatory action.